; and (7) identify any deficiencies, lack of authorities, or limitations in policy or process that limit the ability of any of the departments described in paragraph (6) to address vulnerabilities in the pharmaceutical supply chain identified in the risk assessment, and describe the plans of the departments described in paragraph (6) to mitigate such vulnerabilities. (c) Publication of assessment The risk assessment under subsection (a) (including any updates) shall be publicly available in an unclassified form but may include a classified annex containing any information that the Secretary of Health and Human Services determines to be sensitive. (d) Definitions In this section: (1) Advanced manufacturing The term advanced manufacturing has the meaning given the term advanced and continuous pharmaceutical manufacturing in section 3016(h) of the 21st Century Cures Act ( 21 U.S.C. 399h(h) ). (2) Cybersecurity threat The term cybersecurity threat has the meaning given such term in section 2200 of the Homeland Security Act of 2002 ( 6 U.S.C. 650 ). (3) Drug The term drug has the meaning given such term in section 201(g) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321(g) ). (4) Relevant committees of congress The term relevant committees of Congress means the Committee on Homeland Security and Governmental Affairs, the Committee on Health, Education, Labor, and Pensions, and the Committee on Armed Services of the Senate and the Committee on Homeland Security, the Committee on Energy and Commerce, and the Committee on Armed Services of the House of Representatives. (e) Clarification The participation of the Secretary of Health and Human Services in developing and updating the list of essential medicines under subsection (b)(1) shall be deemed to be full satisfaction of the requirements applicable to such secretary under section 3 of Executive Order 13944 (85 Fed. Reg. 49929).